The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase III randomized, double-blind placebo controlled study of armodafinil (Nuvigil) to reduce cancer-related fatigue in patients with high-grade glioma (Alliance A221101).
 
Alyx B. Porter
Consulting or Advisory Role - Syneos Health
 
Heshan Liu
No Relationships to Disclose
 
Sadhna Kohli
Employment - M2Gen
 
Jane H. Cerhan
No Relationships to Disclose
 
Jeff A. Sloan
No Relationships to Disclose
 
Ryan McMurray
No Relationships to Disclose
 
Jennifer Le-Rademacher
No Relationships to Disclose
 
Charles L. Loprinzi
Consulting or Advisory Role - Asahi Kasei; Disarm Therapeutics; Metys Pharmaceuticals; Mitsubishi Tanabe Pharma; NKMax; OnQuality Pharmaceuticals; PledPharma
Research Funding - Bristol-Myers Squibb (Inst)
Other Relationship - Cynosure/Hologic
 
John L. Villano
No Relationships to Disclose
 
Sani Haider Kizilbash
Research Funding - Apollomics (Inst); Celgene (Inst); DelMar Pharmaceuticals (Inst); Orbus Therapeutics (Inst); Wayshine Biopharma (Inst)
 
Minesh P. Mehta
Leadership - Oncoceutics
Stock and Other Ownership Interests - Oncoceutics
Consulting or Advisory Role - AstraZeneca; Blue Earth Diagnostics; Karyopharm Therapeutics; Tocagen
Research Funding - Novocure (Inst)
Patents, Royalties, Other Intellectual Property - WARF patent 14/934,27, TOPICAL VASOCONSTRITOR PREPARATIONS AND METHODS FOR PROTECTING CELLS DURING CANCER CHEMOTHERAPY AND RADIOTHERAPY
(OPTIONAL) Uncompensated Relationships - Xcision Medical Systems
 
Kurt A. Jaeckle
Stock and Other Ownership Interests - Entegrion
 
Paul D. Brown
Honoraria - UpToDate